AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is currently conducting a Phase III clinical study titled A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death. The study aims to assess the efficacy of combining Baxdrostat with Dapagliflozin in reducing the risk of heart failure and cardiovascular death among patients with type 2 diabetes and established cardiovascular disease.
The intervention being tested involves the use of Baxdrostat and Dapagliflozin, both administered in tablet form. Baxdrostat is being evaluated for its potential to enhance the cardiovascular benefits of Dapagliflozin, a well-known SGLT2 inhibitor used to manage blood sugar levels in type 2 diabetes patients.
This randomized, placebo-controlled study employs a parallel intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment assignments. The primary purpose of the study is prevention, focusing on reducing the incidence of heart failure and cardiovascular death.
The study began on March 14, 2025, and is currently recruiting participants. The primary completion date is yet to be announced, but the last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
The outcome of this study could significantly impact AstraZeneca’s stock performance, as positive results may enhance investor confidence and market positioning in the cardiovascular treatment space. Competitors in the pharmaceutical industry will be closely monitoring these developments, given the potential market implications.
The study is ongoing, and further details are available on the ClinicalTrials portal.